Expert Interview
A look at BNT327, a bispecific antibody in development by BioNTech, and the results presented at the ESMO Congress in patients with NSCLC
Ticker(s): BNTXInstitution: Cleveland Clinic
- Vice Chair of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Center.
- Thoracic medical oncologist with over 20 years of clinical experience; Active clinical investigator in trials involving NSCLC and small cell lung cancer as well as mesothelioma.
- Treats 20-25 new NSCLC patients per month and currently manages over 200 active patients with NSCLC.
How many NSCLC patients do you manage, and what percentage of them have EGFR mutations? Can you describe the current management approach for EGFR-mutated patients, including testing, first-line treatment, and post-Tagrisso options?
What is your view on the dual targeting of VEGF-A and PD-L1 with BNT327? How does this bispecific antibody compare to existing combinations like Avastin plus Keytruda or Tecentriq?
What are your thoughts on the trial design and baseline characteristics for BNT327, particularly in EGFR-mutated patients with brain metastases? How does the breakdown of PD-L1 expression affect interpretation of the trial results?
Given the 61% overall response rate and the gradation by PD-L1 status, what do you think of the efficacy data presented for BNT327? How do these results compare with similar agents like Ivonescimab or Rybrevant plus chemotherapy?
What is your assessment of BNT327's safety profile compared to Rybrevant plus chemotherapy? How might this agent be further developed, especially considering PD-L1 expression levels and the competition from other treatments?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
